Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.

Abstract

Despite current guidelines recommendations about anticoagulant prophylaxis, many studies have shown an high venous thromboembolism (VTE) incidence in patients undergoing total hip and knee arthroplasty. A number of anticoagulants are currently available, but they have some limitations that affect their applicability and consequently their effectiveness. Several new oral anticoagulants (NOACs) have been developed in an attempt to overcome these limitations. Apixaban is a NOAC that selectively inhibits the coagulation factor Xa; it is approved for the prevention of VTE after total hip replacement and total knee replacement surgery. This review examines the results of main trials designed to test efficacy and safety of apixaban in major elective orthopedic surgery.

• Authors: Pietro Maniscalco, Marco Caforio, Davide Imberti, Giuseppe Porcellini, Raffaella Benedetti
• Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (Clin Appl Thromb Hemost) Vol. 21 Issue 2 Pg. 115-9 (Mar 2015) ISSN: 1938-2723 [Electronic] United States
• PMID: 25125051 (Publication Type: Comparative Study, Journal Article, Review)
• Copyright: © The Author(s) 2014.

Chemical References

• Enoxaparin
• Factor Xa Inhibitors
• Pyrazoles
• Pyridones
• apixaban

Topics

• Administration, Oral
• Arthroplasty, Replacement, Hip
• Enoxaparin (adverse effects, therapeutic use)
• Factor Xa Inhibitors (adverse effects, therapeutic use)
• Humans
• Pyrazoles (adverse effects, therapeutic use)
• Pyridones (adverse effects, therapeutic use)
• Venous Thromboembolism (prevention & control)